近期论文
查看导师最新文章
（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）
Bao X*, Liang Y , Chang H, CaiT, Feng B, Gordon K, Zhu Y, Shi H, He Y *, Xie L*. Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): from bench to bedside. 2024 Jan 8;9(1):13. Signal Transduction and Targeted Therapy, 2024 Jan 8;9(1):13. IF: 38.104, SCI1区 （共通信作者)
He Y, Xu W, Xiao Y, Huang H, Gu D, Ren S. Targeting signaling pathways in prostate cancer: mechanisms and clinical trials. Signal Transduction and Targeted Therapy, 2022, 7(1):198. IF: 38.104, SCI1区 （第一&通信作者)
He Y, Wang L, Wei T, Su H, Hollern D, Ma J, Wen S, Xie H, Yan Y, Pan Y, Tang X, Suman V, Carter J, Weinshilboum R, Wang L, Kalari K, Boughey J, Dong H, Ye D, Perou C, Goetz M, Ren S and Huang H. FOXA1 overexpression inhibits interferon signaling and immune response in cancer. Journal of Clinical Investigation, 2021. IF: 19.456, SCI1区（第一作者)
He Y, Wei T, Lin D, Fazli L, Karnes R, Jimenez R, Wang L, Wang L, Gleave M, Wang Y and Huang H. A noncanonical AR addiction drives enzalutamide resistance in prostate cancer. Nature Communications, 2021. IF: 17.694, SCI1区（第一作者)
He Y, Lu J, Ye Z, Hao S, Wang L, Kohli M, Tindall DJ, Li B, Zhu R, Wang L, Huang H. Androgen receptor splice variants bind to constitutively open chromatin and promote abiraterone-resistant growth of prostate cancer. Nucleic Acids Research, 2018. IF:19.16, SCI1区（第一作者)
He Y, Zhao Y, Wang L, Bohrer LR, Pan Y, Wang L, Huang H. LSD1 promotes S-phase entry and tumorigenesis via chromatin co-occupation with E2F1 and selective H3K9 demethylation. Oncogene, 2017. IF: 9.867, SCI1区（第一作者)
He Y, Peng S, Wang J, Chen H, Cong X, Chen A, Hu M, Qin M, Wu H, Gao S, Wang L, Wang X, Yi Z, Liu M. Ailanthone targets p23 to overcome MDV-3100 resistance in castration-resistant prostate cancer. Nature Communications, 2016. IF: 17.694, SCI1区（第一作者)
Blee A*, He Y*, Yang Y*, Ye Z, Yan Y, Pan Y, Ma T, Dugdale J, Kuehn E, Kohli M, Jimenez R, Chen Y, Xu W, Wang L, Huang H. TMPRSS2-ERG controls luminal epithelial lineage and antiandrogen sensitivity in PTEN and TP53-mutated prostate cancer. Clinical Cancer Research, 2018. IF: 13.801, SCI1区(*共同第一作者)
Shi L*, Yan Y*, He Y*, Yan B, Pan Y, Orme J, Zhang J, Xu W, Pang J, Huang H. Mutated SPOP E3 ligase promotes 17βHSD4 protein degradation and drives androgenesis and prostate cancer progression. Cancer Research. 2021., IF: 13.321, SCI1区(*共同第一作者)
Cong X*, He Y*, Wu H*, Wang D, Liu Y, Shao T, Liu M, Yi Z, Zheng J, Peng S, Ding T. Regression of Castration-Resistant Prostate Cancer by a Novel Compound HG122. Frontiers in Oncology, 2021. IF: 6.244, SCI2区(*共同第一作者)
He Y, Liu Y, Lin Q, Zhu J, Zhang Y, Wang L, Ren XL, Ye X. Polydatin suppresses ultraviolet B induced cyclooxygenase 2 expression in vitro and in vivo via reduced production of reactive oxygen species. British Journal of Dermatology, 2012. IF: 11.113, SCI2区（第一作者)
Li G*, He Y*, Zhou W, Wang P, Zhang Y, Tong W, Wu H, Liu M, Ye X, and Chen Y. Identification, synthesis and photo-protection evaluation of aryl thiazole derivatives as a novel series of sunscreens. Heterocycles, 2014. (*共同第一作者)
Wen S, He Y, Wang L, Zhang J, Quan C, Niu Y, Huang H. Aberrant activation of super enhancer and choline metabolism drive antiandrogen therapy resistance in prostate cancer. Oncogene, 2020. IF: 9.867, SCI1区
Shao J, Yan Y, Ding D, Wang D, He Y, Pan Y, Yan W, Kharbanda A, Li H, Huang H. Destruction of DNA-Binding Proteins by Programmable Oligonucleotide PROTAC (O‘PROTAC): Effective Targeting of LEF1 and ERG. Advanced Science, 2021. IF: 17.521, SCI1区
Ma J, Shi Q, Cui G, Sheng H, Botuyan MV, Zhou Y, Yan Y, He Y, Wang L, Wang Y, Mer G, Ye D, Wang C, Huang H. SPOP mutation induces replication over-firing by impairing Geminin ubiquitination and triggers replication catastrophe upon ATR inhibition. Nature Communications, 2021. IF: 17.694, SCI1区
Lin Q, He Y, Wang X, Zhang Y, Hu M, Guo W, He Y, Zhang T, Lai L, Sun Z, Yi Z Liu M, Chen Y. Targeting Pyruvate Carboxylase by a Small Molecule Suppresses Breast Cancer Progression. Advanced Science, 2020. IF: 17.521, SCI1区
Zhang P, Wang D, Zhao Y, Ren S, Gao K, Ye Z, Wang S, Pan CW, Zhu Y, Yan Y, Yang Y, Wu D, He Y, Zhang J, Lu D, Liu X, Yu L, Zhao S, Li Y, Lin D, Wang Y, Wang L, Chen Y, Sun Y, Wang C, Huang H. Intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT-mTORC1 activation. Nature Medicine, 2017. IF: 87.241, SCI1区
Peng S, Wang J, Chen H, Hu P, He X, He Y, Wang M, Tang W, He Q, Wang Y, Xie J, Guo D, Ren S, Liu M, Qiu W, Yi Z. Regression of castration-resistant prostate cancer by a novel compound QW07 targeting androgen receptor N-terminal domain. Cell Biology and Toxicology,2020. IF: 6.691, SCI2区
Zhao Y, Ding L, Wang D, Ye Z, He Y, Ma L, Zhu R, Pan Y, Wu Q, Pang K, Hou X, Weroha SJ, Han C, Coleman R, Coleman I, Karnes RJ, Zhang J, Nelson PS, Wang L, Huang H. EZH2 cooperates with gain-of-function p53 mutants to promote cancer growth and metastasis. EMBO J, 2019. IF: 11.598, SCI1区
Wang J, Xing Y, Wang Y, He Y, Wang L, Peng S, Yang L, Xie J, Li X, Qiu W, Yi Z, Liu M. A novel BMI-1 inhibitor QW24 for the treatment of stem-like colorectal cancer. J Exp Clin Cancer Res, 2019. IF: 11.161, SCI2区
Y Yan Y, An J, Yang Y, Wu D, Bai Y, Cao W, Ma L, He Y, Wang D, and Huang H. Dual inhibition of AKT-mTOR and AR signaling by targeting HDAC3 in PTEN- or SPOP-mutated prostate cancer. EMBO Molecular Medicine, 2018. IF: 12.137, SCI1区
Yang Y, Bai Y, He Y, Zhao Y, Chen J, Ma L, Pan Y, Hinten M, Zhang J, Karnes RJ, Kohli M, Westendorf JJ, Li B, Zhu R, Huang H, Xu W. PTEN loss promotes intratumoral androgen synthesis and tumor microenvironment remodeling via aberrant activation of RUNX2 in castration-resistant prostate cancer. Clinical Cancer Research, 2017. IF: 12.531, SCI1区
Yang Y, Blee AM, Wang D, An J, Pan Y, Yan Y, Ma T, He Y, Dugdale J, Hou X, Zhang J, Weroha SJ, Zhu WG, Wang YA, DePinho RA, Xu W, Huang H. Loss of FOXO1 Cooperates with TMPRSS2-ERG Overexpression to Promote Prostate Tumorigenesis and Cell Invasion. Cancer Research, 2017. IF: 12.531, SCI1区
Wu C, Jin X, Yang J, Yang Y, He Y, Ding L, Pan Y, Chen S, Jiang J, Huang H. Inhibition of EZH2 by chemo- and radiotherapy agents and small molecule inhibitors induces cell death in castration-resistant prostate cancer. Oncotarget, 2016. IF: 5.168
Li P, Liu Y, Wang H, He Y, Wang X, He Y, Lv F, Chen H, Pang X, Liu M, Shi T, Yi Z. PubAngioGen: a database and knowledge for angiogenesis and related diseases. Nucleic Acids Research, 2015; 43:D963-7. IF: 16.971, SCI1区
Qin M, Peng S, Liu N, Hu M, He Y, Li G, Chen H, He Y, Chen A, Wang X, Liu M, Chen Y, Yi Z. LG308, a Novel Synthetic Compound with Antimicrotubule Activity in Prostate Cancer Cells, Exerts Effective Antitumor Activity. Journal of Pharmacology and Experimental Therapeutics, 2015. IF: 4.030, SCI2区
Hu M, Peng S, He Y, Qin M, Cong X, Xing Y, Liu M, Yi Z. Lycorine is a novel inhibitor of the growth and metastasis of hormone-refractory prostate cancer. Oncotarget, 2015. IF: 5.168
Zhang H, Hu LY, Hu K, He Y, Wang S, Luo JP. Hydrogen sulfide promotes wheat seed germination and alleviate oxidative damage against copper stress. Journal of Integrative Plant Biology, 2008. IF: 7.061, SCI2区
京公网安备 11010802027423号